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Abstract
One strategy to manage patients on warfarin starting an interacting drug is to increase the frequency of monitoring.
Another strategy is to adjust warfarin dose around the time patient is started on an interacting medication, which is known
as “preemptive warfarin dose adjustment.” The main objective of this study is to compare preemptive to nonpreemptive
strategy and their impact on the quality of anticoagulation management. This is a retrospective cohort study performed at
the pharmacist-managed anticoagulation clinic in a tertiary hospital in the State of Qatar. Over a 4-year period, 340 patients
were evaluated, and 58 warfarin–drug interaction encounters were identified. Mean age of the patients was (57.7 + 13.7),
and 50% of them were females. Preemptive dose adjustment was used in 17 (29.3%) cases. Incidence of out-of-target
international normalized ratio (INR) was statistically lower in the preemptive arm compared to the control group (41.2%
[7/17] vs 69.2% [27/39], P ¼ .048). Incidence of extreme out-of-target INR was numerically lower in the preemptive arm
compared to the control but did not reach statistical significance (11.8% [2/17] vs 29.3% [12/41], P ¼ .139). Change in
frequency of INR monitoring was not different between the 2 groups. However, overall frequency of INR monitoring after
onset/discontinuation of interacting medication increased compared to baseline (7 [9] vs 21 [16] days, P < .001). Preemptive
strategy was shown in our study to decrease incidence of the out-of-target INR visits, although patients remained in need
for close monitoring.
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Introduction
Warfarin is the mainstay oral anticoagulant medication and one
of the most widely prescribed medications all over the world.1
Because of its narrow therapeutic index and numerous drug and
food interactions, close and consistent monitoring of anticoa-
gulation is mandated to ensure optimal outcomes and minimize
the risks associated with inappropriate management. Interna-
tional normalized ratio (INR) is a reliable surrogate marker that
has been used for decades as an indicator for warfarin thera-
peutic effect and its interaction with food and drugs.2 Drugs
interacting with warfarin can have different mechanisms
including direct pharmacokinetic effect (induction or inhibi-
tion) on the Cytochrome P450 (CYP450) isoenzymes that are
involved in the warfarin metabolism; altered absorption or
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protein binding (eg, cholestyramine); synergistic pharmacody-
namic effect leading to increased risk of bleeding (eg, antipla-
telets); eradication of vitamin K producing intestinal flora (eg,
antibiotics and antifungals). In addition to drug interactions,
most dietary products rich in vitamin K and those altering
CYP enzyme activity can affect warfarin action.3 Whether
the warfarin interaction is drug–drug or drug–food, it may
lead to serious adverse effects—where inhibition of warfarin
effect can lead to treatment failure and recurrence of throm-
boembolic events, while potentiation of warfarin effect can
lead to increased risk of bleeding that may range from minor
to life-threatening bleeding and death.4-6 Although direct oral
anticoagulants (DOACs) such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban offer advantages over
warfarin, their use is still limited due to the increase in gastro-
intestinal side effects, contraindication in patients with major
renal dysfunction, and lack of superiority when compared to
patients with well-managed warfarin therapy.7-10 Lastly, the
cost of DOACs compared to warfarin may be prohibitive for
many patients.11 This has led warfarin to remain as the most
widely prescribed oral anticoagulant in many countries
despite challenges with its management.12-17 Variety of mod-
els are used in warfarin management including patient self-
management, specialized anticoagulation clinics, and
pharmacist-managed anticoagulation clinics.18 Pharmacist-
managed anticoagulation clinic represents a model that
provides patients with more consistent management, closer
monitoring, more education, and awareness especially in
regard to interacting drugs and food which can ultimately
alter warfarin efficacy and safety.18-21
One strategy to manage patients on warfarin starting an
interacting drug is to increase the frequency of monitoring.
Another strategy is to adjust warfarin dose around the time
patient is started on an interacting medication, which is
known as “preemptive warfarin dose adjustment.” Most
studies evaluating these strategies focused on warfarin
interactions with anti-infective agents. In this study, we
explore the effect of warfarin interactions with wide variety
of medications on the quality of anticoagulation manage-
ment in a pharmacist-managed anticoagulation clinic in Al
Wakra hospital, Hamad Medical Corporation (HMC). The
main objective is to compare preemptive to nonpreemptive
strategy and their impact on the quality of anticoagulation
management.
Aim of Study
To evaluate the different strategies used by the clinical phar-
macists working in the anticoagulation clinic and to compare
the incidence of supratherapeutic INR in preemptive dose
adjustment group versus the control group.
Ethics Approval
The institute of research board at HMC approved the study
protocol.
Methods
Design and Setting
The study design was a retrospective cohort study aiming to
compare preemptive versus nonpreemptive strategies in
managing drug interactions with warfarin. A retrospective
chart review of all eligible patients enrolled at Al-Wakrah
pharmacist-managed anticoagulation clinic was performed.
All INR testing in clinic is performed with point-of-care
(POC) instruments. Per clinic policy, all INR values greater
than 5 obtained from POC instruments were verified with
central laboratory assessment. A biweekly calibration is
performed for the clinic’s POC instrument using plasma
calibration sets. In addition to the clinic paper-based flow
sheet, all visits are documented on electronic medical
records (Cerner).
Data Collection and Study Patients
The research subjects included eligible patients managed
between the period of May 2013 to May 2017. A data abstrac-
tion form was developed in order to collect patients’ data from
HMC computer and paper-based database. The following
information was extracted from each eligible record: (1) patient
demographics and baseline characteristics including age, gen-
der, indication for anticoagulation, duration of anticoagulation,
drug interacting with warfarin, degree of interaction, and INR
goal; (2) INR data at baseline (4 weeks prior) and after the
onset/offset of drug interaction.
Patients were eligible for inclusion if they have been
followed at the pharmacist-based anticoagulation clinic at
Al-Wakrah and there was an initiation/discontinuation of a
drug interacting with warfarin. Patients were excluded if they
were less than 18 years of age or if they received anticoagulants
other than warfarin. Anticoagulation clinical and hospital
records were used for screening eligible patients.
Assessment of Outcomes
The primary outcome was to compare the impact of pre-
emptive versus nonpreemptive strategies on the incidence of
out-of-target INR (out-of-target INR was defined as INR
above or below target range by +0.2) as well as the inci-
dence of extreme out-of-range INR values, as defined by an
INR 1.5 or 4.5 (definition previously used by Schulman
et al).22
Secondary outcomes included comparison of the overall
frequency of INR monitoring, incidence of out-of-target
INR and extreme out-of-range INR prior and during the
interaction period. Change in frequency of INR monitoring
in the preemptive versus nonpreemptive strategies was also
compared. We also included a subgroup analysis of the
primary outcomes based on the level of drug interaction.
Levels of drug interactions were identified using LexiComp
definitions. LexiComp interactions module was used to ana-
lyze the interactions.
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Statistical Analysis and Sample Size
Both descriptive and inferential statistical analyses were
applied for the collected data using IBM Statistical Package
for Social Sciences (IBM SPSS version 25 software). Catego-
rical variables were expressed as frequencies and percentages
while continuous variables were expressed either as mean +
standard deviation or median (interquartile range [IQR], for
data that were not normally distributed). t test or Mann-
WhitneyU test (if data were not normally distributed) was used
to compare continuous data. For paired continuous data,
paired-t test or Wilcoxon signed rank test (if data were not
normally distributed) was used. For categorical variables,
either w2 or McNemar (for paired variables) tests were used.
Statistically significant results were determined at a P value of
<.05. All patients who met inclusion/exclusion criteria were
included in the analysis.
Results
Over the period of 4 years (2013-2017), 340 patients were eval-
uated and 58 warfarin–drug interaction encounters were identi-
fied.Mean age of the patientswas (57.7+ 13.7) and 50% of them
were females. Atrial fibrillation/flutter stroke prevention and
treatment of venous thromboembolism were the 2 main warfarin
indications (43.1% and 39.7%, respectively). Majority of the
patients had an INR goal of 2 to 3 (84.5%). Interacting medica-
tions and the number of patients affected by each agent are men-
tioned in Table 1. Initiation of an interacting drug was the main
cause of interaction (84.5%) while the remaining interactions
(15.5%) were due to discontinuation of an interacting drug. Most
of the drug interactions were either grade C (58.6%) or grade D
(39.7%). Preemptive dose adjustment was used in 17 cases
(29.3%). There were no statistical differences between preemp-
tive and control groups in any of the demographic or baseline
characteristics (Table 2). A list of all interacting drugs in our
cohort and their frequency are listed in Table 1.
As expected, the whole cohort’s overall frequency of INR
monitoring after onset/discontinuation of interacting
medication increased compared to baseline (7 [9] vs 21 [16]
days, P < .001). Due to the effect of the interaction on INR
stability, overall incidence of out-of-target INR was statisti-
cally higher after interaction compared to baseline (32
[59.3%] vs 13 [24%], P ¼ .001]. Similarly, incidence of
extreme out-of-range INR was also found to be higher after
interaction compared to baseline but did not reach statistical
significance (13 [23.6%] vs 6 [10.9%], P ¼ .143; Table 3).
When we compared the change in the frequency of INR
monitoring in the preemptive arm to the control arm, there was
no statistical difference between both groups (7.5 [27] vs
8.5 [70], P ¼ .92; Table 4). However, incidence of out-of-
target INR was statistically lower in the preemptive arm com-
pared to the control group (41.2% [7/17] vs 69.2% [27/39],
P ¼ .048; Figure 1) indicating improved INR control with the
preemptive strategy. Incidence of extreme out-of-range INR
was numerically lower in the preemptive arm compared to the
control but did not reach statistical significance (11.8% [2/17]
vs 29.3% [12/41], P ¼ .139).
In a subgroup analysis in patients with grade C interactions,
the incidence of out-of-target INR (more than 0.2 from target)
was significantly lower in preemptive dose adjustment group
compared to the control group (22.2% [2/9] vs 75% [18/24],
P value ¼ .009). Moreover, patients with grade D interactions
had numerically lower incidence of out-of-target INR in pre-
emptive dose adjustment compared to control group but it did
not reach statistical significance as shown in Table 5. Another
subgroup analysis of extreme out of range INR (1.5 or 4.5)
in preemptive dose adjustment group compared to the control
group stratified by the grade of drug interaction with warfarin
showed a lower incidence in patients with preemptive dose
adjustment compared to control group in drug but it did not
reach statistical significance as shown in Table 5.
Discussion
In this research work, we observed an improved INR control
with the preemptive strategy that was evidenced by the
decreased incidence of the out-of-target INR visits. Extreme
out-of-range INR was also numerically lower compared to the
nonpreemptive strategy but did not reach statistical signifi-
cance. Benefit of the use of preemptive warfarin dose adjust-
ment has been studied by others, however, results were
conflicting.23-27 Three of these studies were retrospective
observational studies that focused on preemptive dose reduc-
tion of warfarin in patients initiating metronidazole,23,25 sulfa-
methoxazole-trimethoprim,23,24 and levofloxacin.24 While
2 other studies were randomized controlled trials (RCTs) by
Dowd and colleagues and they compared preemptive warfarin
dose reduction to reactive warfarin dose adjustment in patients
receiving prednisone26 and in patients receiving doxycycline.27
The 3 observational studies indicated that patients with pre-
emptive strategy were more likely to maintain therapeutic INR
and not to have supratherapeutic INR compared to the control
group. These results were more pronounced in patients on
metronidazole and sulfamethoxazole-trimethoprim than in
Table 1. Interacting Medications and Number of Patients Affected.
Interacting Medication Number of Patients
Penicillin 11
Other medicationsa 8
Metronidazole 7
Quinolones 5
Cephalosporins 5
Carbimazole 4
Cotrimoxazole 3
Levothyroxine 2
Omega 3 2
Celecoxib 2
Rifampicin 2
Fluconazole 2
aOther medications ¼ amiodarone, azithromycin, charcoal, celecoxib, diclofe-
nac, digoxin, lansoprazole, ranitidine, torsemide.
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patients on levofloxacin.23-25 On the other hand, both RCTs on
warfarin–prednisone and warfarin–doxycycline interactions,
found more control patients with INR of more than 1 point
over the goal upper limit compared to the intervention group
but these results did not reach statistical significance.26,27
There was also a statistical significance increase in the inci-
dence of subtherapeutic INRs in the preemptive group. Con-
troversy in these studies’ results is likely justified by the
differences in the study design, extent of dose reduction made
in the preemptive arm, measured outcomes, and the studied
drug interaction. For example, medications such as
sulfamethoxazole-trimethoprim and metronidazole are well
known to have higher level of interaction with warfarin and
to induce more consistent elevation in INR.28,29 This justifies
the positive impact of preemptive strategy seen in the research
work studying the warfarin interaction with these drugs. In
our study, all different medications interacting with warfarin
were included. About 20% of these observed interactions,
however, were with metronidazole and sulfamethoxazole-
trimethoprim (Table 1).
Based on our subgroup analysis that stratified interacting
medications according to degree of interaction, a significantly
lower out of range INR was seen in preemptive dose adjust-
ment versus control in category C interaction. This was the
only statistically significant result in this subgroup analysis.
Other results showed some trend of less extreme out of range
Table 3. Effect of Drug Interactions on the INR Monitoring Fre-
quency and Quality of Anticoagulation Management.a
After
Interaction Baseline P Value
INR monitoring interval (days),
median (IQR)
7 (9) 21 (16) P < .001
Incidence of out-of-target INR,
n (%)
32 (59.3%) 13 (24%) P ¼ .001
Incidence of extreme out-of-
range INR, n (%)
13 (23.6%) 6 (10.9%) P ¼ .143
Abbreviations: INR, international normalized ratio; IQR, interquartile range.
a International normalized ratio monitoring intervals were compared using
Wilcoxon signed ranks test while out-of-target INR values and extreme
out-of-range INR values were compared using McNemar test. International
normalized ratio monitoring interval, out-of-target INR, and extreme out-of-
range INR were compared in 48, 54, and 55 cases, respectively. Patients with
missing values were excluded from these analyses.
Table 2. Baseline Characteristics of Patients.
Characteristicsa
Preemptive Adjustment
Group, n ¼ 17
Control Group,
n ¼ 41 P Value Overall, n ¼ 58
Age (years), mean+ SD 53.9 + 13.9 59.3+ 13.5 .17 57.7 + 13.7
Female, n (%) 11 (64.7%) 18 (43.9%) .15 29 (50%)
Indication .32
Atrial fibrillation/flutter 5 (29.4%) 20 (48.8%) 25 (43.1%)
Treatment of VTE 7 (41.2%) 16 (39%) 23 (39.7%)
Valve replacement 3 (17.6%) 3 (7.3%) 6 (10.3%)
Other 2 (11.8%) 2 (4.9%) 4 (6.9%)
Goal INR, n (%) .69
2.0-3.0 14 (82.4%) 35 (85.4%) 49 (84.5%)
2.5-3.5 3 (17.6%) 4 (9.8%) 7 (12.1%)
Other 0 (0%) 2 (4.9%) 2 (3.4%)
INR before interaction, mean + SD 2.3 + 0.6 2.4+ 0.8 .65 2.4 + 0.7
Weekly warfarin dose before interaction (mg), mean + SD 44.3 + 49.3 37.3+ 21.8 .58 39.3 + 32
Cause of interaction, n (%) .43
Initiating an interacting drug 13 (76.5%) 36 (87.8%) 49 (84.5%)
Discontinuing an interacting drug 4 (23.5%) 5 (12.2%) 9 (15.5%)
Categories of drug interactions, n (%) .69
B 0 (0%) 1 (2.4%) 1 (1.7%)
C 9 (52.9%) 25 (61%) 34 (58.6%)
D 8 (47.1%) 15 (36.6%) 23 (39.7%)
Abbreviations: INR, international normalized ratio; IQR, interquartile range; VTE, venous thromboembolism; SD, standard deviation.
aBaseline characteristics are presented based on number of encounters. Categorical variables were compared using w2 or Fischer exact test, as appropriate. Age,
dose, and INR were compared using independent t test and follow-up intervals were compared using Mann-Whitney U test.
Table 4. Effect of Preemptive Dose Adjustment of Warfarin on the
INR Monitoring Frequency.
Preemptive
Adjustment
Group, n ¼ 14
Control
Group,
n ¼ 34
P
Valuea
INR monitoring interval before
interaction (days),median (IQR)
14 (14) 21 (16) .13
Difference in monitoring interval
(days), median (IQR) (after–
before)
7.5 (27) 8.5 (70) .92
Abbreviations: INR, international normalized ratio; IQR, interquartile range.
aMonitoring intervals were compared using Mann-Whitney U test.
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INR in the preemptive dose adjustment group although these
results were not statistically significant (Table 5).
Our study also indicates that warfarin drug interactions
increase the need for frequent INR visits due to instability in
the INR. However, there was still an increased incidence in the
out-of-range INR visits postinteraction compared to baseline.
This result is in alignment with previous report by Raebel et al
where warfarin monitoring in patients receiving antimicrobial
therapy was evaluated.30 The study found that 77% of the
patients were seen within 14 days of the initiation of the inter-
acting medication.
Our study must be taken in context of several limitations.
First, the study was observational in nature and may have been
exposed to selection bias that could impact its internal validity.
Additionally, our study sample may have been inadequate
since it was not powered. Instead, we relied on capturing all
drug interactions that occurred at the clinic since it was
launched. Further, percentage dose reduction or increase was
not always consistent since it was a clinical decision based on
the interacting medication and the patient condition and was
left at the discretion of the pharmacist running the clinic.
Despite these limitations, our study is considered unique
since it is one of few studies that looked at wide variety of
medications interacting with warfarin and was not specific to
1 or 2 medications. There was also a limited attrition and infor-
mation bias since we had good record of patients’ INR at base-
line and after the interaction.
Conclusion
Drug interactions with warfarin are associated with impaired
INR control that requires more frequent follow-up visits to
adjust warfarin dose. Preemptive strategy is shown in our
study to decrease incidence of the out-of-target INR visits,
although patients remained in need for close monitoring.
Future randomized prospective studies are warranted to con-
firm these findings.
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